Keywords: CSL Behring, Corifact, terbutaline, USA, FDA, Congenital Factor XIII defiency, Pre-term labor

US FDA approves CSL Behring’s Corifact; warns on pre-term use of terbutaline

Article | 18 February 2011

Print This

The US Food and Drug Administration has approved Corifact, the first product intended to prevent bleeding in people with the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in